RTOG Foundation Study 3503
Status Date: October 15, 2019 | Status: Completed
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Manmeet Ahluwalia, MD
To determine the efficacy of TTFields Therapy with bevacizumab as measured by the overall survival rate at 6 months from the time of registration.
Confirmation of recurrence or progression on contract MRI of histologically proven GBM or other grade IV malignant glioma.
|Emory University, Winship Cancer Institute
|Froedert and Medical College of Wisconsin
|Medical University of South Carolina
|University of California San Diego Moores Cancer Center
|University of Florida Health Cancer Center
|University of California Irvine, Chao Family Comprehensive Cancer Center
|University of Rochester
|Washington University School of Medicine